$2.09 Billion is the total value of Avoro Capital Advisors LLC's 58 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARRY | Exit | ARRAY BIOPHARMA INCcall | $0 | – | -75,000 | -100.0% | -0.01% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INCcall | $0 | – | -675,000 | -100.0% | -0.02% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS INC | $0 | – | -340,821 | -100.0% | -0.11% | – |
| CLLS | Exit | CELLECTIS S Asponsored ads | $0 | – | -78,289 | -100.0% | -0.15% | – |
| INCY | Exit | INCYTE CORP | $0 | – | -50,000 | -100.0% | -0.31% | – |
| NLNK | Exit | NEWLINK GENETICS CORP | $0 | – | -795,412 | -100.0% | -0.42% | – |
| IMMU | Exit | IMMUNOMEDICS INCcall | $0 | – | -875,000 | -100.0% | -0.53% | – |
| CASC | Exit | CASCADIAN THERAPEUTICS INC | $0 | – | -2,485,272 | -100.0% | -0.60% | – |
| MYOK | Exit | MYOKARDIA INC | $0 | – | -398,207 | -100.0% | -1.09% | – |
| BMY | Exit | BRISTOL MYERS SQUIBB CO | $0 | – | -456,223 | -100.0% | -1.81% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC. | 39 | Q2 2024 | 17.9% |
| MIRATI THERAPEUTICS INC. | 36 | Q4 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 34 | Q2 2024 | 8.0% |
| SAREPTA THERAPUTICS INC | 31 | Q2 2024 | 14.8% |
| ASCENDIS PHARMA | 31 | Q2 2024 | 9.1% |
| ARGENX SE | 29 | Q2 2024 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 29 | Q2 2024 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 26 | Q4 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 25 | Q2 2024 | 7.7% |
| XENON PHARMACEUTICALS INC | 25 | Q2 2024 | 3.6% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Spyre Therapeutics, Inc. | April 23, 2024 | 1,839,138 | 5.1% |
| AMICUS THERAPEUTICS, INC. | February 14, 2024 | 27,400,000 | 9.3% |
| Apellis Pharmaceuticals, Inc. | February 14, 2024 | 13,411,111 | 9.9% |
| Ascendis Pharma A/S | February 14, 2024 | 3,755,555 | 6.5% |
| BIOCRYST PHARMACEUTICALS INC | February 14, 2024 | 13,050,000 | 6.4% |
| CymaBay Therapeutics, Inc. | February 14, 2024 | 16,337,739 | 10.0% |
| IO Biotech, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
| Krystal Biotech, Inc. | February 14, 2024 | 2,565,555 | 9.1% |
| Kymera Therapeutics, Inc. | February 14, 2024 | 3,775,000 | 6.8% |
| MADRIGAL PHARMACEUTICALS, INC. | February 14, 2024 | 2,288,888 | 9.9% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-27 |
| 13F-HR | 2024-08-14 |
| 4 | 2024-06-14 |
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.